WuXi Biologics stock gains 4.60 percent to EUR 5.68

Published on 10/20/2026 at 20:23 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Revenue rose 18.40 percent in the first half of 2026. WuXi Biologics stock costs EUR 5.68 on October 20, 2026, up 4.60 percent versus Tradegate.

Price and growth figures

WuXi Biologics stock gained 4.60 percent versus the Tradegate close of October 19, 2026.
Revenue rose 18.40 percent to RMB 11.79 billion in the first half of 2026.
WuXi Biologics stock costs EUR 5.68 at Lang & Schwarz on October 20, 2026 at 8:16 p.m. CEST, 4.60 percent above the Tradegate close of October 19, 2026.
The reported analyst target rose from HKD 51.10 to HKD 62.00 on October 10, 2026.

WuXi Biologics, KYG970081173, Illustration mit AI erstellt.

WuXi Biologics (ISIN KYG970081173) was trading at EUR 5.68 at Lang & Schwarz on October 20, 2026 at 8:16 p.m. CEST, up 4.60 percent versus the Tradegate close of October 19, 2026 at EUR 5.43. The move gives the stock its strongest daily signal in this report, while the company remains supported by first-half operating growth.

FinancialFilings reported on September 22, 2026 that revenue for the six months ended June 30, 2026 rose 18.40 percent year over year to RMB 11.79 billion. Gross profit increased 28.10 percent to RMB 5.45 billion, and gross margin expanded to 46.20 percent from 42.70 percent.

Profit growth meets a margin test

Adjusted net profit attributable to owners rose 38.40 percent to RMB 3.31 billion in the first half of 2026, compared with RMB 2.39 billion in the same period of 2025, according to FinancialFilings. Reported net profit margin nevertheless declined to 24.70 percent from 27.70 percent, with the report citing unrealized foreign-exchange losses and fair-value losses on equity investments.

Stock position after the move

On the Hong Kong Stock Exchange, WuXi Biologics last traded at HKD 50.05 on October 20, 2026 at 4:08 p.m. HKT. The 52-week range was HKD 28.48 to HKD 58.00, leaving the Hong Kong quote 13.71 percent below its high and 75.72 percent above its low. The market capitalization was HKD 206.0 billion, with a price-to-earnings ratio of 35.78.

What does the target imply?

Simply Wall St reported on October 10, 2026 that an analyst target rose from HKD 51.10 to HKD 62.00. The new target stood 23.88 percent above the HKD 50.05 Hong Kong quote, a comparison that puts the market move beside the latest reported valuation view.

The interim report also recorded 1,064 integrated projects as of June 30, 2026, including 78 late-phase projects and 28 commercial manufacturing projects. Total backlog reached USD 25.1 billion, although the report noted that milestone realization depends on project success and development progress.

Growth remains the central measure

For investors, the key contrast is clear: gross margin improved by 3.50 percentage points, while net margin fell by 3.00 percentage points in the first half of 2026. The current euro quotation and the Hong Kong valuation therefore point to a stock whose operating expansion is being assessed alongside execution and foreign-exchange risks.

WuXi Biologics was trading at EUR 5.68 at Lang & Schwarz on October 20, 2026 at 8:16 p.m. CEST, up 4.60 percent versus the Tradegate close of October 19, 2026 at EUR 5.43. The further course of trading is shown by the continuously updated real-time quote of WuXi Biologics stock.